Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson reported second‑quarter 2026 sales of $25.3 billion, up 6.6% from 2025, with Innovative Medicine up 7.8% and MedTech up 4.5%. Net earnings were $5.53 billion and diluted EPS $2.27, compared with $2.29 a year earlier. On a non‑GAAP basis, adjusted net earnings rose to $7.08 billion and adjusted diluted EPS to $2.90, increases of 5.7% and 4.7%.
For the first six months of 2026, sales reached $49.4 billion, up 8.2%, while GAAP net earnings declined to $10.77 billion and EPS to $4.41. Adjusted diluted EPS for the period was $5.60, up 1.3%. Strong operational performance results in the company increasing 2026 guidance, now estimating reported sales of $100.8–$101.4 billion (midpoint $101.1 billion) and adjusted diluted EPS of $11.60–$11.75 (midpoint $11.68). The release also highlights recent approvals and data for products including TREMFYA, CAPLYTA and the Dual Energy THERMOCOOL SMARTTOUCH SF platform, along with broader Innovative Medicine and MedTech pipeline and investment activity.
JOHNSON & JOHNSON executive Kathryn E. Wengel reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 10,000 employee stock options with an exercise price of $115.67 per share and acquired the same number of common shares.
That same day, she sold 10,000 common shares in open-market transactions, with trades executed at prices between $240.14 and $240.19, according to a weighted-average price footnote. After these transactions, she directly owned 114,287.8735 shares of common stock and held 32,965 stock options outstanding.
She also reported indirect holdings of 281 shares through an ESOP position and 90 shares via a 401(k) plan as of the plan’s May 31, 2026 reporting date.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 161.089 Deferred Share Units as a compensation-related award tied to deferral of his cash retainer under the company’s Deferred Fee Plan for Directors. Following this grant, he holds a total of 6,411.959 Deferred Share Units. These units, including dividend equivalent rights, are to be settled in cash upon the end of his board service and mirror the value of one common share each at settlement.
Johnson & Johnson director Daniel E. Pinto received a grant of 134.241 Deferred Share Units on June 9, 2026, tied to a reference price of $232.79 per unit. After this award, he holds 2,320.824 Deferred Share Units.
The units were acquired by deferring his cash retainer under the company’s Amended and Restated Deferred Fee Plan for Directors. These Deferred Share Units are settled in cash when his board service ends and each unit reflects the fair market value of one share of common stock at settlement, including dividend equivalent rights credited over time.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson reported receiving 214.786 Deferred Share Units on June 9, 2026 as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These units represent deferred cash retainers and are to be settled in cash when her board service ends, bringing her total Deferred Share Units to 15,791.877, including amounts accrued as dividend equivalent rights.
Johnson & Johnson filed a Form 13F reporting institutional holdings. The Form 13F Information Table lists 16 entries with a total market value of $652,355,946. The report was signed by Marc Larkins on 05-13-2026 and names one other included manager: Johnson & Johnson Innovation - JJDC, Inc.
JOHNSON & JOHNSON EVP John C. Reed reported routine equity compensation activity involving restricted share units (RSUs) and tax withholding. On May 1, 2026, RSUs covering 25,255 shares of Common Stock vested and were exercised into shares.
To cover taxes due at vesting, 11,002 shares of Common Stock were withheld at a reference price of $229.85 per share. After these transactions, Reed directly owned 24,911 shares of Johnson & Johnson Common Stock. This reflects RSU vesting and related tax withholding, not an open-market purchase or sale.
Johnson & Johnson reported that Vanguard Capital Management beneficially owned 180,631,228 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 180,631,228 shares and sole voting power for 24,025,858 shares.